Skip navigation

 Login or Register | Member Centre

GlobeInvestorGOLD Canada's most comprehensive investment tool.

 
Change Symbol: Lookup Trade Now

AEterna Zentaris | Headlines

  • Vol:
  • Last Trade:
Search found 99 documents NextNext
1: Ęterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
CNW, February 3, 2010 08:35 AM

2: Ęterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia
CNW, January 29, 2010 08:35 AM

3: Keryx Biopharmaceuticals, Inc. to Conduct Conference Call to Discuss KRX-0401 (Perifosine) Clinical Development Program in Colorectal Cancer
PR NEWSWIRE, January 27, 2010 04:00 PM

4: Ęterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
CNW, January 25, 2010 08:35 AM

5: AEterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
PR NEWSWIRE, January 25, 2010 08:35 AM

6: Keryx Reports Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
PR NEWSWIRE, January 25, 2010 08:30 AM

7: Ęterna Zentaris Receives NASDAQ Notification Related to Minimum Bid Price
CNW, January 22, 2010 04:05 PM

8: AEterna Zentaris Receives NASDAQ Notification Related to Minimum Bid Price
PR NEWSWIRE, January 22, 2010 04:05 PM

9: Ęterna Zentaris Partner, Keryx Biopharmaceuticals, to Present Poster Highlighting Clinical Activity of Perifosine (KRX-0401) at the ASCO 2010 Gastrointestinal Cancers Symposium
CNW, January 21, 2010 08:35 AM

10: AEterna Zentaris Partner, Keryx Biopharmaceuticals, to Present Poster Highlighting Clinical Activity of Perifosine (KRX-0401) at the ASCO 2010 Gastrointestinal Cancers Symposium
PR NEWSWIRE, January 21, 2010 08:35 AM

NextNext
 

Search using one or more of the following options:

Symbol Lookup
 
 
  Search Tips
 
  * Can only be used when searching The Globe and Mail and newswires.

Back to top